Woman in white lab coat looks into microscope

Our 3D ADPKD model system provides significant advancement in throughput and pathophysiologic relevancy.

See How It Works
Quality Communication IconQuality Communication
Exceptional Service IconExceptional Service
Customization IconCustomization

DBM is a boutique biotechnology company founded in 2007 on the principle that if the end goal is to discover and use drugs for human patients, it makes the most sense to integrate the most relevant human cell platforms as early as possible into the drug discovery and validation process. We apply this principle to all our CRO and R&D projects.

Leveraging Human Cell Platform Technologies

DBM's mission is to fill a critical niche within the modern drug discovery industry by specializing in custom human cell engineering and human cell-based drug discovery.

Learn More

News & Publications

2021-2022 Focus – Utility of DBM’s Diseased and Normal Human Cell Platforms and Bioassays in Metabolomics, Genomics, Proteomics and Medium-throughput Screening

DiscoveryBioMed, Inc. has matured into a premier Human Cell Models CRO by growing, expanding and leveraging its diseased and normal human cell cultures, platforms and bioassays into almost every human…

Learn More

2021-2022 Focus – Validation of the Output of Artificial Intelligence-driven Drug Discovery Initiatives with DBM’s Diseased and Normal Human Cell Platforms and Bioassays

As a premier Human Cell Models CRO, a growing sector for DiscoveryBioMed, Inc. is validation of drug targets and drug candidates identified by artificial intelligence (AI)-based inquiry. AI can identify…

Learn More

2021-2022 Focus – Diseased and Normal Human Primary Cell Culture Creation

As a premier Human Cell Models CRO, a continuing focus for DiscoveryBioMed, Inc. is primary human cell culture creation. We have frequent inquiries about our capabilities across multiple tissue types.…

Learn More

We are very positive on your customized and collaborative approach to CRO services projects. Your communication skills are excellent and we can tell that you work on that consistently. These factors helped us to decide to work with you on a long-term project.

Principal from a small Biotechnology company

The human taste bud cell cultures that you are developing and the bioassays that you have developed, along with the growth formats that you are implementing, could be game changers in a vigorous industry involving foods, beverages, food additives, food ingredients and the like.

Consultant familiar with the taste industry

Your company is one of a few if not the only Renal CROs globally and we have been searching for them vigorously recently.

Principal from a large BioPharmaceutical company client

Your 3D ADPKD cystogenesis assays are the most developed and are superior to other laboratories attempting to do the same profiling assays.

Principal from a small Biotechnology company

Your genotyped primary human ADPKD cells have been vitally important for our genomics studies in ADPKD.

Principal from a genomics unit within a large BioPharmaceutical company client

The biomarker data derived from your primary human ADPKD cell cultures from multiple donors matched our data derived from whole PKD kidney tissue.

Principal from a medium-sized Biotechnology company client